NGF and Alzheimer disease: By giving novel insights into the molecular mechanisms underlying the loss/denervation of cholinergic nerve terminals occurring in incipient early/middle-stage of AD neuropathology, these findings from two well-established cellular and animal AD models provide potential therapeutic targets to contrast early cognitive and synaptic dysfunction associated to impairment in NGF/TrkA signaling pathway and selective degeneration of vulnerable BFCNs population.